Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report
Treatment with programmed cell death 1 inhibitors is associated with a wide range of cutaneous immune-related adverse events, with lichenoid eruptions representing one of the major cutaneous toxicities. We describe the case of an 81-year-old man with metastatic melanoma treated with pembrolizumab wh...
Main Authors: | Wilson H Miller, Khashayar Esfahani, Meagan-Helen Henderson Berg, Hanieh Zargham, Robin Billick, Kevin Pehr, Margaret Redpath, Osama Roshdy |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy
by: Marie Donaldson, et al.
Published: (2018-09-01) -
Efficacy of targeted narrowband ultraviolet B therapy in Vitiligo
by: Imran Majid
Published: (2014-01-01) -
Excimer laser therapy and narrowband ultraviolet B therapy for exfoliative cheilitis
by: Bhavnit K. Bhatia, BA, et al.
Published: (2015-06-01) -
Clinicohistopathologic study of lichenoid interface dermatitis
by: Aparna Muralidhar, et al.
Published: (2020-01-01) -
Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment
by: Andrzej Jaworek, et al.
Published: (2020-10-01)